Genetic variation across populations has direct consequences for precision medicine trial design. As patient populations in clinical research become more ethnically and culturally diverse, cultural competency in genomic medicine is a structural requirement for equitable and effective trial execution. This diversity is characterized by distinct cultural backgrounds that considerably influence individuals' reactions to various healthcare services, including the progressively important field of genomic medicine. In this context, cultural competency becomes an essential skill for researchers and healthcare providers. When applied consistently, cultural competence reduces variation in care delivery, improves patient trust, and supports more accurate clinical and genomic decision-making across diverse populations.
Health equity, defined as everyone having the opportunity to be as healthy as possible, has long been a primary goal of public health. Still, across the world, people don't have the same opportunities to see doctors, take part in research, or access medications and genetic testing. This disparity of care can affect rates of disease and disability – and most importantly, hinder quality and length of life.
Our new whitepaper "Inclusive genomics: A path to equitable precision medicine" offers a close look at the intersection of genomic research and diversity. It's an exploration of how embracing the full spectrum of human diversity is not just beneficial but essential for the advancement of precision medicine.
The 34th International Symposium on ALS/MND arrived at a moment of real momentum in ALS research. The field has seen a significant expansion in genetic understanding, growing investment, and the emergence of the first genetically targeted therapies. This year's event underscored that trajectory, commemorating the 30th anniversary of the discovery of SOD1, the first monogenic cause of ALS, and making clear how far the genetic understanding of this disease has come.
As we step into a new era of medical innovation, it's crucial to shine a light on diseases that have long remained in the shadows. Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease also known as motor neuron disease (MND), is one such condition that has challenged medical experts for decades. Today, we’re thrilled to share a beacon of hope in this challenging landscape: Sano’s launch of “Light the Way.”
Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies
- Sano Genetics launches ‘Light The Way’, offering peer support, DNA testing, genetic counseling and education to those diagnosed with or experiencing symptoms of ALS, and those at risk of genetic ALS due to their family history.
- Around one in five ALS cases are now thought to be genetic; 40+ genes have been linked to the disease thanks to new discoveries funded in part by the 2014 ALS ice bucket challenge.*
- Knowing their genetic risk could offer relief to many, while those who test positive may be able to access newly approved therapies, clinical trials and observational studies like Beacon, which charts the psychological impact of ALS genetic testing.
In the ever-evolving landscape of healthcare, precision medicine trials stand out as a beacon of personalised treatment, tailored to the unique genetic and environmental makeup of each individual. But the backbone of these trials isn't just cutting-edge technology or groundbreaking research; it's the patients. Engaging them effectively is both an art and a science. Here, we explore best practices for patient engagement in this dynamic field.
As precision medicine advances from concept to clinical practice, its economic implications are becoming a central question for sponsors, health systems, and policymakers alike. Economic evaluations are used to determine the value of treatments and guide resource allocation. However, applying these evaluations to precision medicine is not straightforward.
In our latest report, we explore the complexities of Amyotrophic Lateral Sclerosis (ALS), offering a comprehensive overview of the disease. From genetic components to the latest FDA-approved treatments, we cover the entire spectrum of ALS research and care.
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a complex liver disease characterized by fat accumulation, inflammation, and fibrosis. With its global prevalence rising alongside obesity and type 2 diabetes rates, the medical community is urgently seeking innovative prediction, diagnosis, and treatment strategies.